Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A.

Blood. 2006 Nov 15;108(10):3472-6. Epub 2006 Jul 25.

2.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

3.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
4.

The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.

Sidon P, El Housni H, Dessars B, Heimann P.

Leukemia. 2006 Sep;20(9):1622. Epub 2006 Jun 15. No abstract available.

PMID:
16775613
5.

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

Scott LM, Scott MA, Campbell PJ, Green AR.

Blood. 2006 Oct 1;108(7):2435-7. Epub 2006 Jun 13.

6.

Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.

Escoffre-Barbe M, Amiot L, Beaucournu P, Jego P, Grulois I, Grosbois B, Bernard M, Fest T, Lamy T, Fardel O.

Am J Hematol. 2006 Jul;81(7):554-6.

7.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP.

Blood. 2006 Oct 1;108(7):2173-81. Epub 2006 Jun 1.

8.

Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.

Thiele J, Kvasnicka HM.

Semin Thromb Hemost. 2006 Apr;32(3):219-30. Review.

PMID:
16673276
9.

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.

Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B.

Leukemia. 2006 Jun;20(6):1181-3. No abstract available.

PMID:
16598303
10.
11.
12.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group.

Lancet. 2005 Dec 3;366(9501):1945-53.

PMID:
16325696
13.

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN.

Blood. 2006 Mar 1;107(5):1864-71. Epub 2005 Oct 25.

14.

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.

Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE.

Haematologica. 2005 Oct;90(10):1315-23.

15.

Chromosomal abnormalities and molecular markers in myeloproliferative disorders.

Bench AJ, Pahl HL.

Semin Hematol. 2005 Oct;42(4):196-205. Review.

PMID:
16210033
16.

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.

Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A.

Br J Haematol. 2005 Oct;131(2):208-13.

PMID:
16197451
17.

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM.

Leukemia. 2005 Oct;19(10):1847-9. No abstract available.

PMID:
16079890
18.

Identification of an acquired JAK2 mutation in polycythemia vera.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ.

J Biol Chem. 2005 Jun 17;280(24):22788-92. Epub 2005 Apr 29.

19.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A.

Blood. 2005 Aug 15;106(4):1207-9. Epub 2005 Apr 28.

20.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

Supplemental Content

Support Center